Extended-interval gentamicin: Population pharmacokinetics in pediatric critical illness

Pediatric Critical Care Medicine

Volumn 11, Issue 2, 2010, Pages 267-274

  Lopez, Sara Arenas ^a   Mulla, Hussain ^b   Durward, Andrew ^a   Tibby, Shane M ^a  

^a EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Aminoglycoside; Child; Critical illness; Gentamicin; Intensive care; Neonate; Pharmacokinetics

Indexed keywords

GENTAMICIN;

AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MONITORING; HUMAN; INFANT; INTENSIVE CARE PSYCHOSIS; KIDNEY FUNCTION; MONTE CARLO METHOD; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 77949441555     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181b80693     Document Type: Article

References (49)

1. British Medical Association and Royal Pharmaceutical Society of Great Britain: British National Formulary for Children 2008. London, Pharmaceutical Press. Available at: http://bnfc.org/bnfc/bnfc/current/3832.htm. Accessed January 8, 2008
2. Bates RD, Nahata MC: Once-daily administration of aminoglycosides. Ann Pharmacother 1994; 28:757-766
3. Scheetz MH, Hurt KM, Noskin GA, et al: Applying antimicrobial pharmacodynamics to resistant Gram-negative pathogens. Am J Health Syst Pharm 2006; 63:1346-1360
4. Daikos GL, Lolans VT, Jackson GG: Firstexposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991; 35:117-123
5. De Broe ME: Renal injury due to environmental toxins, drugs, and contrast agents. In: Atlas of Diseases of the Kidney. Volume 1. Berl T, Bonventre JV (Eds). ISN Informatics Commission and NKF cyberNephrology. Available at: http://www.kidneyatlas.org/ toc.htm. Accessed January 8, 2009
6. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al: Extended-interval aminoglycoside administration for children: A metaanalysis. Pediatrics 2004; 114:e111-e118
7. Nestaas E, Bangstad H-J, Sandvik L, et al: Aminoglycoside extended interval dosing in neonates is safe and effective: A metaanalysis. Arch Dis Child Fetal Neonatal Ed 2005; 90:F294-F300
8. Rao SC, Ahmed M, Hagan R: One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2006; 1:CD005091
9. Barza M, Ioannidis JPA, Cappelleri JC, et al: Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ 1996; 312: 338-345
10. Ali MZ, Goetz MB: A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809
11. Postovsky S, Ben Arush MW, Kassis E, et al: Pharmacokinetic analysis of gentamicin thrice and single daily dosage in pediatric cancer patients. Pediatr Hematol Oncol 1997; 14:547-554
12. Shahid M, Cooke R: Is a once daily dose of gentamicin safe and effective in the treatment of UTI in infants and children? Arch Dis Child 2007; 92:823-824
13. English M, Mohammed S, Ross A, et al: A randomised, controlled trial of once daily and multi-dose daily gentamicin in young Kenyan infants. Arch Dis Child 2004; 89: 665-669
14. Khan AM, Ahmed T, Alam NH, et al: Extended- interval gentamicin administration in malnourished children. J Trop Pediatr 2006; 52:179-184
15. Marik PE, Lipman J, Kobilski S, et al: A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and pediatric patients. J Antimicrob Chemother 1991; 28:753-764
16. Vallés J, Rello J, Ochagavía A, et al: Community- acquired bloodstream infection in critically ill adult patients: Impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123:1615-1624
17. Leibovici L, Shraga I, Drucker M, et al: The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-386
18. Hansen M, Christrup LL, Jarløv JO, et al: Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand 2001; 45:734-740
19. Goldstein B, Giroir B, Randolph A; International Consensus Conference on Pediatric Sepsis: International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8
20. Hing JP, Woolfrey SG, Greenslade D, et al: Analysis of toxicokinetic data using NONMEM: Impact of quantification limit and replacement strategies for censored data. J Pharmacokinet Pharmacodyn 2001; 28:465-479
21. Duval V, Karlsson MO: Impact of omission or replacement of data below the limit of quantification on parameter estimates in a twocompartment model. Pharm Res 2002; 19: 1835-1840
22. Beal SL: Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28:481-504
23. Bergstrand M, Plan E, Kjellsson M, et al: A comparison of methods for handling of data below the limit of quantification in NONMEM VI. Abstracts of the Annual Meeting of the Population Approach Group in Europe. 2007, p 16, abstract 1201. Available at: http://www.page-meeting.org/ ?abstract-1201. Accessed January 8, 2009
24. Anderson BJ, Holford NH: Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48:303-332
25. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Available at: http://217.70.33.99/Eucast2/. Accessed June 2008
26. Bell DM: Promoting appropriate antimicrobial drug use: Perspective from the Centers for Disease Control and Prevention. Clin Infect Dis 200115; S33:S245-S250
27. Behrman RE, Kliegman RM, Jenson HB (Eds): Nelson's Textbook of Pediatrics. 17th ed. Philadelphia, WB Saunders, 2004
28. The Johns Hopkins Hospital: The Harriet Lane Handbook. 17th ed. St Louis, Mosby, 2005
29. Tomlin S: Paediatric Formulary. 7th ed. London, Guy's and St Thomas,' King's College and University Lewisham Hospitals, 2005
30. de Jager P, van Altena R: Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6:622-627
31. Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy: Importance of the ratio of the peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99
32. Craig WA, Redington J, Ebert SC: Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27(Suppl C):29-40
33. Drusano GL, Ambrose PG, Bhavnani SM, et al: Back to the future: Using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45:753-760
34. Uijtendaal EV, Rademaker CM, Schobben AF, et al: Once-daily versus multiple-daily gentamicin in infants and children. Ther Drug Monit 2001; 23:506-513
35. Elhanan K, Siplovich L, Raz R: Gentamicin once-daily versus thrice-daily in children. J Antimicrob Chemother 1995; 35:327-332
36. de Hoog M, Mouton JW, van den Anker JN: New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med 2005; 10:185-194
37. Lanao JM, Calvo MV, Mesa JA, et al: Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. J Antimicrob Chemother 2004; 54: 193-198
38. Kashuba AD, Nafziger AN, Drusano GI, et al: Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623-629
39. Bass KD, Larkin SE, Paap C, Haase GM: Pharmacokinetics of once-daily gentamicin dosing in pediatric patients. J Pediatr Surg 1998; 33:1104-1107
40. Tang GJ, Tang JJ, Lin BS, et al: Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand 1999; 43:726-730
41. Nagai J, Takano M: Molecular aspects of renal handling of aminoglycosides and strategies for preventing nephrotoxicity. Drug Metab Pharmacokin 2004; 19:159-170
42. Giuliano RA, Verpooten GA, De Broe ME: The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. Am J Kidney Dis 1986; 8:297-303
43. Verpooten GA, Giuliano RA, Verbist L, et al: A once-daily dosage schedule decreases the accumulation of gentamicin and netilmicin in the renal cortex of humans. Clin Pharmacol Ther 1989; 44:1-5
44. Giuliano RA, Verpooten GA, Verbist L, et al: In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236:470-475
45. Nicolau DP, Freeman CD, Belliveau PP, et al: Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995; 39:650-655
46. O'Neil WG: Aminoglycoside induced ototoxicity. Toxicology 2008; 249:91-96
47. Seemungal BM, Bronstein AM: Aminoglycoside ototoxicity: Vestibular function is also vulnerable. BMJ 2007; 335:952
48. Pierrat A, Gravier E, Saunders C, et al: Predicting GFR in children and adults: A comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas. Kidney Int 2003; 64:1425-1436
49. Rhodin MM, Anderson BJ, Peters AM, et al: Human renal function maturation: A quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24: 67-67